Identification

Name
Pindolol
Accession Number
DB00960  (APRD00678)
Type
Small Molecule
Groups
Approved
Description

A moderately lipophilic beta blocker (adrenergic beta-antagonists). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638)

Structure
Thumb
Synonyms
  • 1-(1H-indol-4-yloxy)-3-(isopropylamino)propan-2-ol
  • 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)-propan-2-ol
  • 1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]propan-2-ol
  • 4-(2-hydroxy-3-isopropylaminopropoxy)-indole
  • Pindololum
External IDs
BRN 1536506 / CCRIS 9215 / DL-LB-46 / HSDB 6539 / LB 46 / LB-46
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dom-pindololTablet5 mgOralDominion Pharmacal1998-09-17Not applicableCanada
Dom-pindololTablet10 mgOralDominion Pharmacal1998-09-17Not applicableCanada
Dom-pindololTablet15 mgOralDominion Pharmacal1998-09-17Not applicableCanada
Gen-pindolol Tab 15mgTablet15 mgOralGenpharm Ulc1994-12-312010-08-04Canada
Mylan-pindololTablet10 mgOralMylan Pharmaceuticals1994-12-312012-10-19Canada
Mylan-pindololTablet5 mgOralMylan Pharmaceuticals1994-12-312012-10-19Canada
Nu-pindol Tab 10mgTablet10 mgOralNu Pharm Inc1990-12-312012-09-04Canada
Nu-pindol Tab 15mgTablet15 mgOralNu Pharm Inc1990-12-312012-09-04Canada
Nu-pindol Tab 5mgTablet5 mgOralNu Pharm Inc1990-12-312012-09-04Canada
Pindolol-10 Tab 10mgTablet10 mgOralPro Doc Limitee1989-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-pindol Tab 10mgTablet10 mgOralApotex Corporation1988-12-31Not applicableCanada
Apo-pindol Tab 15mgTablet15 mgOralApotex Corporation1988-12-31Not applicableCanada
Apo-pindol Tab 5mgTablet5 mgOralApotex Corporation1988-12-31Not applicableCanada
PindololTablet5 mg/1OralCarilion Materials Management1992-09-03Not applicableUs
PindololTablet5 mg/1OralMylan Pharmaceuticals1992-09-03Not applicableUs00378 0052 01 nlmimage10 e40df26f
PindololTablet10 mg/1OralANI Pharmaceuticals, Inc.2017-05-08Not applicableUs
PindololTablet5 mg/1OralNostrum Laboratories, Inc.2016-02-01Not applicableUs
PindololTablet5 mg/1OralSun Pharmaceutical Industries Limited1994-01-27Not applicableUs
PindololTablet10 mg/1OralMylan Pharmaceuticals1992-09-03Not applicableUs00378 0127 01 nlmimage10 873ec3c6
PindololTablet10 mg/1OralNostrum Laboratories, Inc.2016-02-01Not applicableUs
International/Other Brands
Betapindol / Blockin L / Blocklin L / Calvisken / Decreten / Durapindol / Glauco-Visken / Pectobloc / Pinbetol / Prinodolol / Pynastin / Visken
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Viskazide 10/25tabPindolol (10 mg) + Hydrochlorothiazide (25 mg)TabletOralTribute Pharmaceuticals1983-12-31Not applicableCanada
Viskazide 10/50tabPindolol (10 mg) + Hydrochlorothiazide (50 mg)TabletOralTribute Pharmaceuticals1983-12-31Not applicableCanada
Categories
UNII
BJ4HF6IU1D
CAS number
13523-86-9
Weight
Average: 248.3208
Monoisotopic: 248.152477894
Chemical Formula
C14H20N2O2
InChI Key
JZQKKSLKJUAGIC-UHFFFAOYSA-N
InChI
InChI=1S/C14H20N2O2/c1-10(2)16-8-11(17)9-18-14-5-3-4-13-12(14)6-7-15-13/h3-7,10-11,15-17H,8-9H2,1-2H3
IUPAC Name
1-(1H-indol-4-yloxy)-3-[(propan-2-yl)amino]propan-2-ol
SMILES
CC(C)NCC(O)COC1=CC=CC2=C1C=CN2

Pharmacology

Indication

For the management of hypertension, edema, ventricular tachycardias, and atrial fibrillation.

Structured Indications
Pharmacodynamics

Pindolol is a non-selective beta-adrenergic antagonist (beta-blocker) which possesses intrinsic sympathomimetic activity (ISA) in therapeutic dosage ranges but does not possess quinidine-like membrane stabilizing activity. Pindolol impairs AV node conduction and decreases sinus rate and may also increase plasma triglycerides and decrease HDL-cholesterol levels. Pindolol is nonpolar and hydrophobic, with low to moderate lipid solubility. Pindolol has little to no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, pindolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action.

Mechanism of action

Pindolol non-selectively blocks beta-1 adrenergic receptors mainly in the heart, inhibiting the effects of epinephrine and norepinephrine resulting in a decrease in heart rate and blood pressure. By binding beta-2 receptors in the juxtaglomerular apparatus, Pindolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production and therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively.

TargetActionsOrganism
ABeta-1 adrenergic receptor
partial agonist
Human
ABeta-2 adrenergic receptor
partial agonist
Human
U5-hydroxytryptamine receptor 1A
antagonist
Human
U5-hydroxytryptamine receptor 1B
other/unknown
Human
UBeta-3 adrenergic receptor
agonist
Human
Absorption

Rapidly and reproducibly absorbed (bioavailability greater than 95%).

Volume of distribution
  • 2 L/kg
Protein binding

40%

Metabolism

Hepatic. In man, 35% to 40% is excreted unchanged in the urine and 60% to 65% is metabolized primarily to hydroxy-metabolites which are excreted as glucuronides and ethereal sulfates.

Route of elimination

Pindolol undergoes extensive metabolism in animals and man. In man, 35% to 40% is excreted unchanged in the urine and 60% to 65% is metabolized primarily to hydroxy-metabolites which are excreted as glucuronides and ethereal sulfates. About 6% to 9% of an administered intravenous dose is excreted by the bile into the feces.

Half life

3 to 4 hours

Clearance
  • 50-300 mL/min [cirrhotic patients]
Toxicity

LD50=263 mg/kg (orally in rats). Signs of overdose include excessive bradycardia, cardiac failure, hypotension, and bronchospasm.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Pindolol Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Pindolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Pindolol.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Pindolol.Experimental
AbirateroneThe serum concentration of Pindolol can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Pindolol is combined with Acebutolol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Pindolol.Approved
AcemetacinAcemetacin may decrease the antihypertensive activities of Pindolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Pindolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Pindolol.Approved
AcetohexamidePindolol may increase the hypoglycemic activities of Acetohexamide.Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Pindolol is combined with Acetylcholine.Approved
AcetyldigitoxinPindolol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinPindolol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Pindolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Pindolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Pindolol.Experimental, Investigational
AlaproclateThe serum concentration of Pindolol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Pindolol.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Pindolol.Approved
AlfentanilAlfentanil may increase the bradycardic activities of Pindolol.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Pindolol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Pindolol.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Pindolol is combined with Aliskiren.Approved, Investigational
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Pindolol.Experimental
AlprenololAlprenolol may increase the hypotensive activities of Pindolol.Approved, Withdrawn
AmbenoniumAmbenonium may increase the bradycardic activities of Pindolol.Approved
AmbrisentanPindolol may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostinePindolol may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Pindolol.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Pindolol.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Pindolol.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Pindolol.Approved, Illicit
AmodiaquineThe metabolism of Pindolol can be decreased when combined with Amodiaquine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Pindolol.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Pindolol is combined with Amyl Nitrite.Approved
AndrographolideAndrographolide may decrease the antihypertensive activities of Pindolol.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Pindolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Pindolol.Approved
ApocyninApocynin may decrease the antihypertensive activities of Pindolol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Pindolol is combined with Apraclonidine.Approved
ApremilastApremilast may decrease the antihypertensive activities of Pindolol.Approved, Investigational
ArecolineThe risk or severity of adverse effects can be increased when Pindolol is combined with Arecoline.Experimental
AripiprazoleAripiprazole may increase the hypotensive activities of Pindolol.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Pindolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Pindolol.Approved, Investigational
ArtemetherThe metabolism of Pindolol can be decreased when combined with Artemether.Approved
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Pindolol.Approved
AtomoxetineThe metabolism of Pindolol can be decreased when combined with Atomoxetine.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Pindolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Pindolol.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Pindolol is combined with Azilsartan medoxomil.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Pindolol.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Pindolol.Experimental
BarbitalBarbital may increase the hypotensive activities of Pindolol.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Pindolol.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Pindolol.Approved, Investigational
BendazacBendazac may decrease the antihypertensive activities of Pindolol.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Pindolol.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Pindolol.Withdrawn
BenorilateBenorilate may decrease the antihypertensive activities of Pindolol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Pindolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved, Illicit
BepridilPindolol may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BeractantPindolol may increase the bradycardic activities of Beractant.Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Pindolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Pindolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Pindolol.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Pindolol.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Pindolol.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Pindolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Pindolol.Investigational
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Pindolol.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Pindolol.Approved, Investigational
BQ-123Pindolol may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the bradycardic activities of Pindolol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Pindolol.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Pindolol.Experimental
BromfenacBromfenac may decrease the antihypertensive activities of Pindolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Pindolol.Investigational
BucindololPindolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Pindolol.Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Pindolol.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Pindolol.Approved
BunazosinPindolol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Pindolol.Approved, Investigational
BupranololPindolol may increase the hypotensive activities of Bupranolol.Approved
BupropionThe metabolism of Pindolol can be decreased when combined with Bupropion.Approved
CabergolinePindolol may increase the vasoconstricting activities of Cabergoline.Approved
CadralazineCadralazine may increase the hypotensive activities of Pindolol.Experimental
CafedrinePindolol may increase the hypotensive activities of Cafedrine.Investigational
CalfactantPindolol may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Pindolol is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Pindolol.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Pindolol.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Pindolol is combined with Captopril.Approved
CarbacholThe risk or severity of adverse effects can be increased when Pindolol is combined with Carbachol.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Pindolol.Experimental
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Pindolol.Approved
CarbutamidePindolol may increase the hypoglycemic activities of Carbutamide.Experimental
CaroxazoneCaroxazone may increase the hypotensive activities of Pindolol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Pindolol.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Pindolol.Approved
CarvedilolPindolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Pindolol.Experimental
CelecoxibThe metabolism of Pindolol can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololPindolol may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibPindolol may increase the bradycardic activities of Ceritinib.Approved
CevimelineThe risk or severity of adverse effects can be increased when Pindolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Pindolol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Pindolol.Approved, Vet Approved
ChlorproethazineChlorproethazine may increase the hypotensive activities of Pindolol.Experimental
ChlorpromazineThe metabolism of Pindolol can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamidePindolol may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Pindolol.Approved
CholecalciferolThe metabolism of Pindolol can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Pindolol.Approved
CicletaninePindolol may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Pindolol is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Pindolol.Approved
CimetidineThe metabolism of Pindolol can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Pindolol can be decreased when combined with Cinacalcet.Approved
CitalopramThe metabolism of Pindolol can be decreased when combined with Citalopram.Approved
ClemastineThe metabolism of Pindolol can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Pindolol is combined with Clevidipine.Approved
ClobazamThe metabolism of Pindolol can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Pindolol.Approved, Investigational
ClomipramineThe metabolism of Pindolol can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Pindolol.Approved
CloranololPindolol may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Pindolol can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Pindolol can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Pindolol can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Pindolol can be decreased when combined with Cocaine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Pindolol.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Pindolol.Vet Approved
CrizotinibPindolol may increase the bradycardic activities of Crizotinib.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Pindolol.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Pindolol.Investigational
CyclopenthiazidePindolol may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideCyclothiazide may increase the hypotensive activities of Pindolol.Approved
CymarinPindolol may increase the bradycardic activities of Cymarin.Experimental
D-LimoneneD-Limonene may decrease the antihypertensive activities of Pindolol.Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Pindolol is combined with Dapagliflozin.Approved
DapoxetineThe serum concentration of Pindolol can be increased when it is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Pindolol can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Pindolol can be increased when it is combined with Darunavir.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of Pindolol.Approved
DecamethoniumDecamethonium may increase the bradycardic activities of Pindolol.Approved
DelaprilPindolol may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe metabolism of Pindolol can be decreased when combined with Delavirdine.Approved
DemecariumDemecarium may increase the bradycardic activities of Pindolol.Approved
DeserpidinePindolol may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Pindolol.Approved
DesipramineThe metabolism of Pindolol can be decreased when combined with Desipramine.Approved
DeslanosidePindolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Pindolol can be increased when it is combined with Desvenlafaxine.Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Pindolol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Pindolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Pindolol.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Pindolol is combined with Diclofenamide.Approved
diethylnorsperminePindolol may increase the hypotensive activities of diethylnorspermine.Investigational
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Pindolol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Pindolol.Approved
DigitoxinPindolol may increase the bradycardic activities of Digitoxin.Approved
DigoxinDigoxin may increase the bradycardic activities of Pindolol.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Pindolol.Investigational
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Pindolol.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Pindolol is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Pindolol can be decreased when combined with Diphenhydramine.Approved
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Pindolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Pindolol.Approved
DistigmineDistigmine may increase the bradycardic activities of Pindolol.Experimental
DonepezilDonepezil may increase the bradycardic activities of Pindolol.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Pindolol.Approved
DosulepinThe metabolism of Pindolol can be decreased when combined with Dosulepin.Approved
DoxazosinPindolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DronedaroneDronedarone may increase the bradycardic activities of Pindolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Pindolol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved, Investigational
DuloxetinePindolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Pindolol.Investigational
E-6201E-6201 may decrease the antihypertensive activities of Pindolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Pindolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Pindolol.Approved
EfonidipinePindolol may increase the hypotensive activities of Efonidipine.Approved
EliglustatThe metabolism of Pindolol can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Pindolol is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Pindolol.Approved, Vet Approved
EnalaprilatPindolol may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Pindolol.Experimental
EpanololPindolol may increase the hypotensive activities of Epanolol.Experimental
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved, Nutraceutical, Withdrawn
EpibatidineThe risk or severity of adverse effects can be increased when Pindolol is combined with Epibatidine.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Pindolol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Pindolol.Approved
EpoprostenolPindolol may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Pindolol.Approved
Ergoloid mesylatePindolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovinePindolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Pindolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Pindolol.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Pindolol.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Pindolol.Experimental
EtodolacEtodolac may decrease the antihypertensive activities of Pindolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Pindolol.Approved
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
EtoperidoneThe serum concentration of Pindolol can be increased when it is combined with Etoperidone.Approved
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Pindolol.Approved
exisulindexisulind may decrease the antihypertensive activities of Pindolol.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Pindolol.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Pindolol is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Pindolol.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Pindolol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Pindolol.Approved
FentanylFentanyl may increase the bradycardic activities of Pindolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Pindolol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Pindolol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Pindolol.Experimental
Ferulic acidPindolol may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pindolol.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Pindolol.Approved
FingolimodPindolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Pindolol.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Pindolol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Pindolol.Experimental
FluoxetineThe metabolism of Pindolol can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Pindolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Pindolol.Approved, Investigational
FluvoxamineThe metabolism of Pindolol can be decreased when combined with Fluvoxamine.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Pindolol.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Pindolol.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Pindolol.Approved, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Pindolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Pindolol.Approved
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Pindolol.Approved, Nutraceutical
GitoformatePindolol may increase the bradycardic activities of Gitoformate.Experimental
GlibornuridePindolol may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazidePindolol may increase the hypoglycemic activities of Gliclazide.Approved
GlipizidePindolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidonePindolol may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepidePindolol may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburidePindolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Pindolol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Pindolol.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Pindolol.Approved
GuanazodinePindolol may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Pindolol.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved, Investigational
GuanoclorPindolol may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzPindolol may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanPindolol may increase the hypotensive activities of Guanoxan.Experimental
HaloperidolThe metabolism of Pindolol can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Pindolol.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Pindolol.Experimental
HexamethoniumPindolol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Pindolol.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Pindolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Pindolol.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Pindolol.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Pindolol is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Pindolol is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Pindolol.Approved
HydroxychloroquineThe metabolism of Pindolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Pindolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Pindolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Pindolol.Approved
IloprostIloprost may increase the hypotensive activities of Pindolol.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Pindolol.Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Pindolol.Experimental
ImipramineThe metabolism of Pindolol can be decreased when combined with Imipramine.Approved
IndalpineThe serum concentration of Pindolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Pindolol.Approved
IndenololPindolol may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Pindolol can be decreased when combined with Indinavir.Approved
IndobufenIndobufen may decrease the antihypertensive activities of Pindolol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Pindolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Pindolol.Withdrawn
IndoraminPindolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin PorkPindolol may increase the hypoglycemic activities of Insulin Pork.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Pindolol.Experimental
IproclozideIproclozide may increase the hypotensive activities of Pindolol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Pindolol.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Pindolol is combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Pindolol.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Pindolol.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Pindolol.Approved, Withdrawn
IsoniazidThe metabolism of Pindolol can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Pindolol.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Pindolol is combined with Isosorbide Mononitrate.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Pindolol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Pindolol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Pindolol.Approved
IvabradinePindolol may increase the bradycardic activities of Ivabradine.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Pindolol.Experimental
KetanserinKetanserin may increase the hypotensive activities of Pindolol.Investigational
KetoconazoleThe metabolism of Pindolol can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Pindolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Pindolol.Approved
LabetalolPindolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipinePindolol may increase the hypotensive activities of Lacidipine.Approved
LacosamidePindolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
Lanatoside CPindolol may increase the bradycardic activities of Lanatoside C.Experimental
LanreotidePindolol may increase the bradycardic activities of Lanreotide.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Pindolol.Approved, Investigational
LeflunomideLeflunomide may decrease the antihypertensive activities of Pindolol.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Pindolol.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Pindolol is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Pindolol.Approved
LevodopaPindolol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevomilnacipranThe serum concentration of Pindolol can be increased when it is combined with Levomilnacipran.Approved
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Pindolol.Approved, Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Pindolol.Approved, Vet Approved
LinsidominePindolol may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Pindolol.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Pindolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Pindolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Pindolol.Experimental
LopinavirThe metabolism of Pindolol can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Pindolol can be decreased when combined with Lorcaserin.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Pindolol.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Pindolol.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Pindolol.Approved
LucinactantPindolol may increase the bradycardic activities of Lucinactant.Approved
LumefantrineThe metabolism of Pindolol can be decreased when combined with Lumefantrine.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Pindolol.Approved, Investigational
MacitentanPindolol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Pindolol.Approved
MalathionMalathion may increase the bradycardic activities of Pindolol.Approved, Investigational
ManidipinePindolol may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Pindolol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Pindolol.Approved
MebanazineMebanazine may increase the hypotensive activities of Pindolol.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pindolol.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Pindolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Pindolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Pindolol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Pindolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Pindolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Pindolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Pindolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Pindolol.Approved
MetahexamidePindolol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Pindolol.Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Pindolol is combined with Methacholine.Approved
MethadoneThe metabolism of Pindolol can be decreased when combined with Methadone.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Pindolol.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Pindolol.Approved
MethohexitalMethohexital may increase the hypotensive activities of Pindolol.Approved
MethoserpidinePindolol may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineThe metabolism of Pindolol can be decreased when combined with Methotrimeprazine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Pindolol.Approved
Methyl salicylateMethyl salicylate may increase the bradycardic activities of Pindolol.Approved, Vet Approved
MethyldopaThe risk or severity of adverse effects can be increased when Pindolol is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Pindolol.Investigational
MethylergometrinePindolol may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Pindolol.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Pindolol.Approved
MetildigoxinPindolol may increase the bradycardic activities of Metildigoxin.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Pindolol is combined with Metipranolol.Approved
MetoclopramideMetoclopramide may increase the bradycardic activities of Pindolol.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Pindolol.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Pindolol.Approved, Investigational
MetyrosinePindolol may increase the hypotensive activities of Metyrosine.Approved
MibefradilPindolol may increase the hypotensive activities of Mibefradil.Withdrawn
MidodrinePindolol may increase the bradycardic activities of Midodrine.Approved
MidostaurinThe metabolism of Pindolol can be decreased when combined with Midostaurin.Approved
MilnacipranThe serum concentration of Pindolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Pindolol.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Pindolol.Approved
MirabegronThe metabolism of Pindolol can be decreased when combined with Mirabegron.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Pindolol.Investigational
MizoribineMizoribine may decrease the antihypertensive activities of Pindolol.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Pindolol.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Pindolol.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Pindolol.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Pindolol.Approved
MoricizineMoricizine may increase the hypotensive activities of Pindolol.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Pindolol.Approved, Investigational
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
MuzoliminePindolol may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Pindolol.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Pindolol.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Pindolol.Approved
NadololThe risk or severity of adverse effects can be increased when Pindolol is combined with Nadolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Pindolol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Pindolol.Approved
NaftopidilPindolol may increase the hypotensive activities of Naftopidil.Investigational
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Pindolol.Approved, Vet Approved
NebivololThe risk or severity of adverse effects can be increased when Pindolol is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Pindolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Pindolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Pindolol.Approved
NesiritideThe risk or severity of adverse effects can be increased when Pindolol is combined with Nesiritide.Approved, Investigational
NevirapineThe metabolism of Pindolol can be decreased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Pindolol.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Pindolol.Approved
NicorandilNicorandil may increase the hypotensive activities of Pindolol.Approved
NicotineThe risk or severity of adverse effects can be increased when Pindolol is combined with Nicotine.Approved
NifedipineNifedipine may increase the hypotensive activities of Pindolol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Pindolol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Pindolol.Approved
NiguldipinePindolol may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Pindolol can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipinePindolol may increase the hypotensive activities of Nilvadipine.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Pindolol.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Pindolol.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Pindolol.Approved
NitrendipinePindolol may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Pindolol.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Pindolol.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Pindolol.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Pindolol.Approved
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
ObinutuzumabPindolol may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Pindolol.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Pindolol.Approved, Investigational
OleandrinPindolol may increase the bradycardic activities of Oleandrin.Experimental
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Pindolol.Approved, Investigational
OlopatadineOlopatadine may decrease the antihypertensive activities of Pindolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Pindolol.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Pindolol.Investigational
OrgoteinOrgotein may decrease the antihypertensive activities of Pindolol.Vet Approved
OuabainPindolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Pindolol.Approved
OxprenololPindolol may increase the hypotensive activities of Oxprenolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Pindolol.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pindolol.Approved, Vet Approved
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
PanobinostatThe serum concentration of Pindolol can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Pindolol is combined with Papaverine.Approved
ParaoxonParaoxon may increase the bradycardic activities of Pindolol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Pindolol.Approved
PargylinePargyline may increase the hypotensive activities of Pindolol.Approved
ParoxetineThe metabolism of Pindolol can be decreased when combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Pindolol.Investigational
PasireotidePindolol may increase the bradycardic activities of Pasireotide.Approved
Peginterferon alfa-2bThe serum concentration of Pindolol can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Pindolol is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Pindolol.Approved, Vet Approved
PentoliniumPindolol may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Pindolol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Pindolol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Pindolol.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Pindolol.Approved
PeruvosidePindolol may increase the bradycardic activities of Peruvoside.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Pindolol.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Pindolol.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Pindolol.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Pindolol.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Pindolol.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Pindolol.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Pindolol.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Pindolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Pindolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Pindolol.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Pindolol.Withdrawn
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Pindolol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Pindolol.Investigational
PirlindolePirlindole may increase the hypotensive activities of Pindolol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Pindolol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Pindolol.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Pindolol.Withdrawn
PolythiazidePindolol may increase the hypotensive activities of Polythiazide.Approved
Poractant alfaPindolol may increase the bradycardic activities of Poractant alfa.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Pindolol.Approved, Investigational
PranoprofenPranoprofen may decrease the antihypertensive activities of Pindolol.Experimental
PrazosinPindolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Pindolol can be decreased when combined with Primaquine.Approved
PrimidonePrimidone may increase the hypotensive activities of Pindolol.Approved, Vet Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Pindolol.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Pindolol.Experimental
PromazineThe metabolism of Pindolol can be decreased when combined with Promazine.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Pindolol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Pindolol.Approved
PropafenoneThe serum concentration of Pindolol can be increased when it is combined with Propafenone.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Pindolol.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Pindolol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Pindolol.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Pindolol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Pindolol.Experimental
ProscillaridinPindolol may increase the bradycardic activities of Proscillaridin.Experimental
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Pindolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Pindolol.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Pindolol is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Pindolol.Approved, Investigational
QuinidineThe metabolism of Pindolol can be decreased when combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Pindolol.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Pindolol.Approved
RanolazineThe metabolism of Pindolol can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Pindolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Pindolol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pindolol.Approved
RemikirenRemikiren may increase the hypotensive activities of Pindolol.Approved
RescinnaminePindolol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Pindolol.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Pindolol.Experimental, Investigational
RifampicinThe serum concentration of Pindolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Pindolol can be decreased when it is combined with Rifapentine.Approved
RilmenidineRilmenidine may increase the hypotensive activities of Pindolol.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Pindolol is combined with Riociguat.Approved
RisperidonePindolol may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Pindolol can be decreased when combined with Ritonavir.Approved, Investigational
RituximabPindolol may increase the hypotensive activities of Rituximab.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Pindolol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Pindolol.Investigational, Withdrawn
RolapitantThe metabolism of Pindolol can be decreased when combined with Rolapitant.Approved
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pindolol.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Pindolol.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Pindolol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Pindolol.Approved
SafrazineSafrazine may increase the hypotensive activities of Pindolol.Withdrawn
SalicylamideSalicylamide may decrease the antihypertensive activities of Pindolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Pindolol.Approved, Vet Approved
SalsalateSalsalate may decrease the antihypertensive activities of Pindolol.Approved
SaprisartanPindolol may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalSecobarbital may increase the hypotensive activities of Pindolol.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Pindolol.Approved, Investigational, Vet Approved
SelexipagPindolol may increase the hypotensive activities of Selexipag.Approved
SemapimodSemapimod may decrease the antihypertensive activities of Pindolol.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Pindolol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Pindolol.Investigational
SertralineThe metabolism of Pindolol can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Pindolol.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Pindolol.Approved, Investigational
SilodosinPindolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SitaxentanPindolol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Pindolol.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Pindolol.Approved
SpiraprilPindolol may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Pindolol.Approved
SRT501SRT501 may decrease the antihypertensive activities of Pindolol.Investigational
StiripentolThe metabolism of Pindolol can be decreased when combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Pindolol.Approved
SufentanilSufentanil may increase the bradycardic activities of Pindolol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Pindolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Pindolol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Pindolol.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Pindolol.Experimental
TacrineTacrine may increase the bradycardic activities of Pindolol.Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Pindolol.Approved, Investigational
TalinololPindolol may increase the hypotensive activities of Talinolol.Investigational
TamsulosinPindolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Pindolol.Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Pindolol is combined with Telmisartan.Approved, Investigational
TemocaprilPindolol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapTenidap may decrease the antihypertensive activities of Pindolol.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Pindolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Pindolol.Vet Approved
TerazosinPindolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbinafineThe metabolism of Pindolol can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Pindolol.Approved
TerlipressinPindolol may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatinePindolol may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Pindolol.Approved, Investigational, Withdrawn
TheodrenalinePindolol may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThiamylal may increase the hypotensive activities of Pindolol.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Pindolol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Pindolol.Withdrawn
ThiopentalThiopental may increase the hypotensive activities of Pindolol.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Pindolol.Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Pindolol.Approved
TibolonePindolol may increase the hypotensive activities of Tibolone.Approved
TiclopidineThe metabolism of Pindolol can be decreased when combined with Ticlopidine.Approved
TicrynafenPindolol may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Pindolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Pindolol.Investigational
TipranavirThe metabolism of Pindolol can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Pindolol.Approved, Investigational
TolazamidePindolol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineTolazoline may increase the hypotensive activities of Pindolol.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pindolol.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Pindolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Pindolol.Approved
TolonidinePindolol may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Pindolol.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Pindolol.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Pindolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Pindolol.Experimental
TranylcypromineThe metabolism of Pindolol can be decreased when combined with Tranylcypromine.Approved
TravoprostTravoprost may increase the hypotensive activities of Pindolol.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Pindolol.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Pindolol.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Pindolol.Approved
TribenosideTribenoside may decrease the antihypertensive activities of Pindolol.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Pindolol.Vet Approved
TrichlormethiazidePindolol may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Pindolol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Pindolol.Approved, Vet Approved
TrimazosinPindolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Pindolol.Approved
TriptolideTriptolide may decrease the antihypertensive activities of Pindolol.Investigational
TubocurarineTubocurarine may increase the bradycardic activities of Pindolol.Approved
UdenafilUdenafil may increase the antihypertensive activities of Pindolol.Approved, Investigational
UnoprostonePindolol may increase the hypotensive activities of Unoprostone.Approved
UrapidilPindolol may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Pindolol.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Pindolol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Pindolol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Pindolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe metabolism of Pindolol can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Pindolol.Approved
VincaminePindolol may increase the hypotensive activities of Vincamine.Experimental
VinpocetinePindolol may increase the hypotensive activities of Vinpocetine.Investigational
XipamidePindolol may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Pindolol.Approved, Vet Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Pindolol.Approved
ZileutonZileuton may decrease the antihypertensive activities of Pindolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Pindolol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Pindolol can be decreased when combined with Ziprasidone.Approved
ZofenoprilPindolol may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracZomepirac may decrease the antihypertensive activities of Pindolol.Withdrawn
Food Interactions
  • Magnesium, potassium and zinc needs increased.
  • Take without regard to meals. Avoid alcohol.

References

Synthesis Reference
US3471515
General References
Not Available
External Links
Human Metabolome Database
HMDB15095
KEGG Drug
D00513
KEGG Compound
C07445
PubChem Compound
4828
PubChem Substance
46508362
ChemSpider
4662
BindingDB
50019443
ChEBI
8214
ChEMBL
CHEMBL500
Therapeutic Targets Database
DAP000025
PharmGKB
PA450966
IUPHAR
91
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Pindolol
ATC Codes
C07AA03 — PindololC07CA03 — Pindolol and other diuretics
AHFS Codes
  • 24:24.00
PDB Entries
Not Available
FDA label
Not Available
MSDS
Download (74.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceAmphetamine-Related Disorders / Moods Disorders / Substance-Related Disorders1
1Unknown StatusTreatmentHealthy Volunteers1
2CompletedTreatmentAntidepressant Treatment Response / Major Depressive Disorder (MDD)1
2, 3TerminatedTreatmentUnipolar Depression1
Not AvailableCompletedBasic ScienceHealthy Volunteers1
Not AvailableTerminatedTreatmentHypertensive / Microvascular Angina1
Not AvailableTerminatedTreatmentMajor Depressive Disorder (MDD)1

Pharmacoeconomics

Manufacturers
  • Genpharm pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Nostrum laboratories inc
  • Purepac pharmaceutical co
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Novartis pharmaceuticals corp
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg/1
TabletOral5 mg/1
TabletOral10 mg
TabletOral15 mg
TabletOral5 mg
TabletOral
Prices
Unit descriptionCostUnit
Visken 15 mg Tablet1.52USD tablet
Visken 10 mg Tablet1.05USD tablet
Pindolol 10 mg tablet1.0USD tablet
Pindolol 5 mg tablet0.73USD tablet
Apo-Pindol 15 mg Tablet0.61USD tablet
Gen-Pindolol 15 mg Tablet0.61USD tablet
Novo-Pindol 15 mg Tablet0.61USD tablet
Nu-Pindol 15 mg Tablet0.61USD tablet
Pms-Pindolol 15 mg Tablet0.61USD tablet
Sandoz Pindolol 15 mg Tablet0.61USD tablet
Visken 5 mg Tablet0.61USD tablet
Apo-Pindol 10 mg Tablet0.42USD tablet
Gen-Pindolol 10 mg Tablet0.42USD tablet
Novo-Pindol 10 mg Tablet0.42USD tablet
Nu-Pindol 10 mg Tablet0.42USD tablet
Pms-Pindolol 10 mg Tablet0.42USD tablet
Sandoz Pindolol 10 mg Tablet0.42USD tablet
Apo-Pindol 5 mg Tablet0.24USD tablet
Gen-Pindolol 5 mg Tablet0.24USD tablet
Novo-Pindol 5 mg Tablet0.24USD tablet
Nu-Pindol 5 mg Tablet0.24USD tablet
Pms-Pindolol 5 mg Tablet0.24USD tablet
Sandoz Pindolol 5 mg Tablet0.24USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)171 °CPhysProp
water solubility7880 mg/LNot Available
logP1.75SANGSTER (1994)
Caco2 permeability-4.78ADME Research, USCD
pKa9.25SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.861 mg/mLALOGPS
logP2.17ALOGPS
logP1.69ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area57.28 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity71.46 m3·mol-1ChemAxon
Polarizability28.27 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9951
Blood Brain Barrier+0.6929
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.6667
P-glycoprotein inhibitor INon-inhibitor0.9272
P-glycoprotein inhibitor IINon-inhibitor0.9423
Renal organic cation transporterNon-inhibitor0.8179
CYP450 2C9 substrateNon-substrate0.8315
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.708
CYP450 1A2 substrateNon-inhibitor0.7809
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.5
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8331
Ames testNon AMES toxic0.9218
CarcinogenicityNon-carcinogens0.9367
BiodegradationNot ready biodegradable0.9843
Rat acute toxicity2.9438 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9404
hERG inhibition (predictor II)Non-inhibitor0.5774
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)
Download (8.77 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-01b9-2900000000-e773b852c7d4839b531d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-01c3-1900000000-97bebf43acd96bd5cf5b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-01ba-0920000000-9c68ad2e49235b630737
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-01b9-0900000000-e0edd57b20d4dcecb440
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0002-1690000000-c5bffa0f5938ebc6de4b

Taxonomy

Description
This compound belongs to the class of chemical entities known as indoles. These are compounds containing an indole moiety, which consists of pyrrole ring fused to benzene to form 2,3-benzopyrrole.
Kingdom
Chemical entities
Super Class
Organic compounds
Class
Organoheterocyclic compounds
Sub Class
Indoles and derivatives
Direct Parent
Indoles
Alternative Parents
Alkyl aryl ethers / Benzenoids / Pyrroles / Heteroaromatic compounds / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Indole / Alkyl aryl ether / Benzenoid / Pyrrole / Heteroaromatic compound / Secondary alcohol / 1,2-aminoalcohol / Azacycle / Secondary amine / Ether
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
indoles, secondary amine (CHEBI:8214 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Partial agonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Joseph SS, Lynham JA, Molenaar P, Grace AA, Colledge WH, Kaumann AJ: Intrinsic sympathomimetic activity of (-)-pindolol mediated through a (-)-propranolol-resistant site of the beta1-adrenoceptor in human atrium and recombinant receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003 Dec;368(6):496-503. Epub 2003 Nov 8. [PubMed:14608456 ]
  3. Doggrell SA: Effects of (+/-)- (+)- and (-)-metoprolol, (+/-)- (+)- and (-)-pindolol, (+/-)-mepindolol and (+/-)-bopindolol on the rat left atria and portal vein. Gen Pharmacol. 1991;22(6):1169-77. [PubMed:1687398 ]
  4. Berendsen HH, Broekkamp CL, Van Delft AM: Antagonism of 8-OH-DPAT-induced behaviour in rats. Eur J Pharmacol. 1990 Oct 2;187(1):97-103. [PubMed:2148726 ]
  5. Watkins DJ, Lawrence AJ, Lewis SJ, Jarrott B: Loss of [125I]-pindolol binding to beta-adrenoceptors on rat nodose ganglion after chronic isoprenaline treatment. J Auton Nerv Syst. 1996 Aug 27;60(1-2):12-6. [PubMed:8884690 ]
  6. Brodde OE, Michel MC, Wang XL, Zerkowski HR: Chronic beta-adrenoceptor antagonist treatment modulates human cardiac and vascular beta-adrenoceptor density in a subtype-selective fashion. J Hypertens Suppl. 1988 Dec;6(4):S497-500. [PubMed:2907348 ]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Partial agonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Rubenstein LA, Zauhar RJ, Lanzara RG: Molecular dynamics of a biophysical model for beta2-adrenergic and G protein-coupled receptor activation. J Mol Graph Model. 2006 Dec;25(4):396-409. Epub 2006 Mar 30. [PubMed:16574446 ]
  2. Dejgaard A, Liggett SB, Christensen NJ, Cryer PE, Hilsted J: Adrenergic receptors are a fallible index of adrenergic denervation hypersensitivity. Scand J Clin Lab Invest. 1991 Dec;51(8):659-66. [PubMed:1666931 ]
  3. Wheeldon NM, Newnham DM, Fraser GC, McDevitt DG, Lipworth BJ: The effect of pindolol on creatine kinase is not due to beta 2-adrenoceptor partial agonist activity. Br J Clin Pharmacol. 1991 Jun;31(6):723-4. [PubMed:1678274 ]
  4. Doggrell SA: Effects of (+/-)- (+)- and (-)-metoprolol, (+/-)- (+)- and (-)-pindolol, (+/-)-mepindolol and (+/-)-bopindolol on the rat left atria and portal vein. Gen Pharmacol. 1991;22(6):1169-77. [PubMed:1687398 ]
  5. Doggrell SA: Relaxant and beta 2-adrenoceptor blocking activities of (+/- )-, (+)- and (-)-pindolol on the rat isolated aorta. J Pharm Pharmacol. 1990 Jun;42(6):444-6. [PubMed:1979630 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Smeraldi E, Benedetti F, Barbini B, Campori E, Colombo C: Sustained antidepressant effect of sleep deprivation combined with pindolol in bipolar depression. A placebo-controlled trial. Neuropsychopharmacology. 1999 Apr;20(4):380-5. [PubMed:10088139 ]
  2. Haddjeri N, de Montigny C, Blier P: Modulation of the firing activity of rat serotonin and noradrenaline neurons by (+/-)pindolol. Biol Psychiatry. 1999 May 1;45(9):1163-9. [PubMed:10331108 ]
  3. Gobert A, Millan MJ: Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and 5-HT1B receptors. Neuropsychopharmacology. 1999 Aug;21(2):268-84. [PubMed:10432475 ]
  4. Andree B, Thorberg SO, Halldin C, Farde L: Pindolol binding to 5-HT1A receptors in the human brain confirmed with positron emission tomography. Psychopharmacology (Berl). 1999 Jun;144(3):303-5. [PubMed:10435400 ]
  5. Fornal CA, Martin FJ, Metzler CW, Jacobs BL: Pindolol suppresses serotonergic neuronal activity and does not block the inhibition of serotonergic neurons produced by 8-hydroxy-2-(di-n-propylamino)tetralin in awake cats. J Pharmacol Exp Ther. 1999 Oct;291(1):229-38. [PubMed:10490909 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1B
Uniprot ID
P28222
Uniprot Name
5-hydroxytryptamine receptor 1B
Molecular Weight
43567.535 Da
References
  1. Dawson LA, Nguyen HQ: The role of 5-HT(1A) and 5-HT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (+/-)pindolol. Neuropharmacology. 2000 Apr 3;39(6):1044-52. [PubMed:10727715 ]
  2. Ariani K, Hamblin MW, Tan GL, Stratford CA, Ciaranello RD: G protein dependent alterations in [125I]iodocyanopindolol and +/- cyanopindolol binding at 5-HT1B binding sites in rat brain membranes. Neurochem Res. 1989 Sep;14(9):835-43. [PubMed:2512511 ]
  3. Leonhardt S, Herrick-Davis K, Titeler M: Detection of a novel serotonin receptor subtype (5-HT1E) in human brain: interaction with a GTP-binding protein. J Neurochem. 1989 Aug;53(2):465-71. [PubMed:2664084 ]
  4. Herrick-Davis K, Titeler M, Leonhardt S, Struble R, Price D: Serotonin 5-HT1D receptors in human prefrontal cortex and caudate: interaction with a GTP binding protein. J Neurochem. 1988 Dec;51(6):1906-12. [PubMed:3141589 ]
  5. Terron JA, Lopez-Munoz FJ, Hong E, Villalon CM: 2-(2-Aminoethyl)-quinoline (D-1997): a novel agonist at 5-hydroxytryptamine1-like receptors in the canine basilar artery. Arch Int Pharmacodyn Ther. 1994 Jan-Feb;327(1):56-68. [PubMed:7944828 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
Gene Name
ADRB3
Uniprot ID
P13945
Uniprot Name
Beta-3 adrenergic receptor
Molecular Weight
43518.615 Da
References
  1. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN: Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):151-9. Epub 2004 Jan 17. [PubMed:14730417 ]
  2. Feve B, Emorine LJ, Lasnier F, Blin N, Baude B, Nahmias C, Strosberg AD, Pairault J: Atypical beta-adrenergic receptor in 3T3-F442A adipocytes. Pharmacological and molecular relationship with the human beta 3-adrenergic receptor. J Biol Chem. 1991 Oct 25;266(30):20329-36. [PubMed:1682311 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:49